COMPOSITIONS AND METHODS COMPRISING MAGNETIC RESONANCE CONTRAST AGENTS

Thomas J Meade (Inventor), Teresa Woodruff (Inventor)

Research output: Patent

Abstract

Cell-permeable steroid hormone-targeted magnetic resonance imaging contrast agents. #healthcare #mri #imaging Abstract: Northwestern researchers have synthesized Gd(III)-chelated steroids that target steroid hormone receptors, including progesterone, estrogen and androgen receptors. The compositions provide novel contrast agents for MRI diagnosis. The water soluble complexes are cell-permeable and label cells and tissues expressing the targeted receptor at lower in vitro and in vivo toxicity than the more hydrophobic ProGlo MRI agent. Receptor status can be used to diagnose, non-invasively, prevalent diseases, such as breast, ovarian, endometrial and prostate cancers, as well as a measure of receptor-positive or -negative status to determine the best course of treatment. Inventors: Teresa Woodruff Thomas Meade Preeti Sukerkar Jiyoun Lee Applications: Diagnosis of common steroid-related diseases Determination of receptor-positive or receptor-negative tumor status Detection, characterization and monitoring of steroid-related diseases Advantages: Non-invasive Enables targeted imaging Enables spatial and temporal imaging Publication: Chem Biol. 2007 Jul;14(7):824-34 Bioconjugate Chem. 2011, 22, 2304-2316 IP Status Issued US Patent No:8,580,231 Contact Information: Allan Nader, Ph.D. Invention Manager e) a-nader@northwestern.edu (p) 847-491-4456
Original languageEnglish
Patent number8580231
StatePublished - Jan 10 2013

Fingerprint

Contrast Media
Magnetic Resonance Spectroscopy
Steroids
Inventors
Hormones
Steroid Receptors
Androgen Receptors
Progesterone Receptors
Endometrial Neoplasms
Estrogen Receptors
Ovarian Neoplasms
Prostatic Neoplasms
Research Personnel
Magnetic Resonance Imaging
Breast Neoplasms
Delivery of Health Care
Water
Neoplasms
Therapeutics

Cite this

@misc{1759c28e083b43e9800159db8f256cab,
title = "COMPOSITIONS AND METHODS COMPRISING MAGNETIC RESONANCE CONTRAST AGENTS",
abstract = "Cell-permeable steroid hormone-targeted magnetic resonance imaging contrast agents. #healthcare #mri #imaging Abstract: Northwestern researchers have synthesized Gd(III)-chelated steroids that target steroid hormone receptors, including progesterone, estrogen and androgen receptors. The compositions provide novel contrast agents for MRI diagnosis. The water soluble complexes are cell-permeable and label cells and tissues expressing the targeted receptor at lower in vitro and in vivo toxicity than the more hydrophobic ProGlo MRI agent. Receptor status can be used to diagnose, non-invasively, prevalent diseases, such as breast, ovarian, endometrial and prostate cancers, as well as a measure of receptor-positive or -negative status to determine the best course of treatment. Inventors: Teresa Woodruff Thomas Meade Preeti Sukerkar Jiyoun Lee Applications: Diagnosis of common steroid-related diseases Determination of receptor-positive or receptor-negative tumor status Detection, characterization and monitoring of steroid-related diseases Advantages: Non-invasive Enables targeted imaging Enables spatial and temporal imaging Publication: Chem Biol. 2007 Jul;14(7):824-34 Bioconjugate Chem. 2011, 22, 2304-2316 IP Status Issued US Patent No:8,580,231 Contact Information: Allan Nader, Ph.D. Invention Manager e) a-nader@northwestern.edu (p) 847-491-4456",
author = "Meade, {Thomas J} and Teresa Woodruff",
note = "filingdate: 2012-7-17 issueddate: 2013-11-12 Status: published attorneydocketnumber: 2008-067-03; 8580231",
year = "2013",
month = "1",
day = "10",
language = "English",
type = "Patent",

}

TY - PAT

T1 - COMPOSITIONS AND METHODS COMPRISING MAGNETIC RESONANCE CONTRAST AGENTS

AU - Meade, Thomas J

AU - Woodruff, Teresa

N1 - filingdate: 2012-7-17 issueddate: 2013-11-12 Status: published attorneydocketnumber: 2008-067-03

PY - 2013/1/10

Y1 - 2013/1/10

N2 - Cell-permeable steroid hormone-targeted magnetic resonance imaging contrast agents. #healthcare #mri #imaging Abstract: Northwestern researchers have synthesized Gd(III)-chelated steroids that target steroid hormone receptors, including progesterone, estrogen and androgen receptors. The compositions provide novel contrast agents for MRI diagnosis. The water soluble complexes are cell-permeable and label cells and tissues expressing the targeted receptor at lower in vitro and in vivo toxicity than the more hydrophobic ProGlo MRI agent. Receptor status can be used to diagnose, non-invasively, prevalent diseases, such as breast, ovarian, endometrial and prostate cancers, as well as a measure of receptor-positive or -negative status to determine the best course of treatment. Inventors: Teresa Woodruff Thomas Meade Preeti Sukerkar Jiyoun Lee Applications: Diagnosis of common steroid-related diseases Determination of receptor-positive or receptor-negative tumor status Detection, characterization and monitoring of steroid-related diseases Advantages: Non-invasive Enables targeted imaging Enables spatial and temporal imaging Publication: Chem Biol. 2007 Jul;14(7):824-34 Bioconjugate Chem. 2011, 22, 2304-2316 IP Status Issued US Patent No:8,580,231 Contact Information: Allan Nader, Ph.D. Invention Manager e) a-nader@northwestern.edu (p) 847-491-4456

AB - Cell-permeable steroid hormone-targeted magnetic resonance imaging contrast agents. #healthcare #mri #imaging Abstract: Northwestern researchers have synthesized Gd(III)-chelated steroids that target steroid hormone receptors, including progesterone, estrogen and androgen receptors. The compositions provide novel contrast agents for MRI diagnosis. The water soluble complexes are cell-permeable and label cells and tissues expressing the targeted receptor at lower in vitro and in vivo toxicity than the more hydrophobic ProGlo MRI agent. Receptor status can be used to diagnose, non-invasively, prevalent diseases, such as breast, ovarian, endometrial and prostate cancers, as well as a measure of receptor-positive or -negative status to determine the best course of treatment. Inventors: Teresa Woodruff Thomas Meade Preeti Sukerkar Jiyoun Lee Applications: Diagnosis of common steroid-related diseases Determination of receptor-positive or receptor-negative tumor status Detection, characterization and monitoring of steroid-related diseases Advantages: Non-invasive Enables targeted imaging Enables spatial and temporal imaging Publication: Chem Biol. 2007 Jul;14(7):824-34 Bioconjugate Chem. 2011, 22, 2304-2316 IP Status Issued US Patent No:8,580,231 Contact Information: Allan Nader, Ph.D. Invention Manager e) a-nader@northwestern.edu (p) 847-491-4456

M3 - Patent

M1 - 8580231

ER -